Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.

Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, Smereczynska M, Karlsson KA, Clark WM Jr, Steplewski Z, et al.

Cancer Res. 1987 Mar 1;47(5):1229-33.

3.

Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Ohta S, Honda A, Tokutake Y, Yoshida H, Hanai N.

Cancer Immunol Immunother. 1993;36(4):260-6.

PMID:
8439988
4.

Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.

Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ.

Clin Immunol Immunopathol. 1987 Nov;45(2):214-29.

PMID:
3665201
5.
6.

Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.

Katano M, Jien M, Irie RF.

Eur J Cancer Clin Oncol. 1984 Aug;20(8):1053-9.

PMID:
6540688
7.
8.

Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.

Abdel-Wahab Z, Li WP, Darrow T, Nudelman ED, Towell A, Seigler HF.

Melanoma Res. 1993 Dec;3(6):415-23.

PMID:
8161881
9.
11.

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

Harel W, Shau H, Hadley CG, Morgan AC Jr, Reisfeld RA, Cheresh DA, Mitchell MS.

Cancer Res. 1990 Oct 1;50(19):6311-5.

12.

Human monoclonal antibody to tumor-associated ganglioside GD2.

Katano M, Saxton RE, Irie RF.

J Clin Lab Immunol. 1984 Nov;15(3):119-26.

PMID:
6099419
13.

Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.

Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA.

Cancer Res. 1989 Jun 1;49(11):2857-61.

15.
16.

Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.

Kanazawa J, Ohta S, Shitara K, Fujita F, Fujita M, Hanai N, Akinaga S, Okabe M.

Cancer Immunol Immunother. 2000 Jul;49(4-5):253-8.

PMID:
10941908
17.

Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.

Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H, Tada N, Furukawa K, Tai T.

Int J Oncol. 2003 Aug;23(2):381-8.

PMID:
12851687
18.

Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft.

Katano M, Saxton RE, Tsuchida T, Irie RF.

Jpn J Cancer Res. 1986 Jun;77(6):584-94.

PMID:
3089993
19.

Supplemental Content

Support Center